PDGFR-alpha inhibits melanoma growth via CXCL10/IP-10: a multi- omics  approach

Daniela D’Arcangelo; Francesco Facchiano; Giovanni Nassa; Andrea Stancato; Annalisa Antonini; Stefania Rossi; Cinzia Senatore; Martina Cordella; Claudio Tabolacci; Annamaria Salvati; Roberta Tarallo; Alessandro Weisz; Angelo M. Facchiano; Antonio Facchiano

doi:10.18632/oncotarget.12629

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

PDGFR-alpha inhibits melanoma growth via CXCL10/IP-10: a multi-omics approach

Daniela D’Arcangelo _, Francesco Facchiano, Giovanni Nassa, Andrea Stancato, Annalisa Antonini, Stefania Rossi, Cinzia Senatore, Martina Cordella, Claudio Tabolacci, Annamaria Salvati, Roberta Tarallo, Alessandro Weisz, Angelo M. Facchiano and Antonio Facchiano

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:77257-77275. https://doi.org/10.18632/oncotarget.12629

Metrics: PDF 2322 views | HTML 3044 views | ?

Abstract

Daniela D’Arcangelo1, Francesco Facchiano2, Giovanni Nassa3,4, Andrea Stancato1, Annalisa Antonini1, Stefania Rossi2, Cinzia Senatore2, Martina Cordella2, Claudio Tabolacci2, Annamaria Salvati3, Roberta Tarallo3, Alessandro Weisz3, Angelo M. Facchiano5, Antonio Facchiano1

1Istituto Dermopatico dell’Immacolata, IDI-IRCCS, Fondazione Luigi Maria Monti, Rome, Italy

2Dipartimento Ematologia, Oncologia e Medicina Molecolare, Istituto Superiore di Sanità, Rome, Italy

3Laboratory of Molecular Medicine and Genomics, Department of Medicine and Surgery,University of Salerno, Baronissi (SA), Italy

4Genomix4Life srl, Department of Medicine and Surgery, University of Salerno, Baronissi (SA), Italy

5National Research Council Institute of Food Science, Avellino, Italy

Correspondence to:

Daniela D’Arcangelo, email: [email protected]

Antonio Facchiano, email: [email protected]

Keywords: cancer, omics, angiogenesis, miRNA, melanoma

Received: April 15, 2016 Accepted: September 25, 2016 Published: October 13, 2016

ABSTRACT

Melanoma is the most aggressive skin-cancer, showing high mortality at advanced stages. Platelet Derived Growth Factor Receptor-alpha (PDGFR-alpha) potently inhibits melanoma- and endothelium-proliferation and its expression is significantly reduced in melanoma-biopsies, suggesting that melanoma progression eliminates cells expressing PDGFR-alpha. In the present study transient overexpression of PDGFR-alpha in endothelial (HUVEC) and melanoma (SKMel-28, A375, Preyer) human-cells shows strong anti-proliferative effects, with profound transcriptome and miRNome deregulation. PDGFR-alpha overexpression strongly affects expression of 82 genes in HUVEC (41 up-, 41 down-regulated), and 52 genes in SKMel-28 (43 up-, 9 down-regulated). CXCL10/IP-10 transcript showed up to 20 fold-increase, with similar changes detectable at the protein level. miRNA expression profiling in cells overexpressing PDGFR-alpha identified 14 miRNAs up- and 40 down-regulated, with miR-503 being the most down-regulated (6.4 fold-reduction). miR-503, miR-630 and miR-424 deregulation was confirmed by qRT-PCR. Interestingly, the most upregulated transcript (i.e., CXCL10/IP-10) was a validated miR-503 target and CXCL10/IP-10 neutralization significantly reverted the anti-proliferative action of PDGFR-alpha, and PDGFR-alpha inhibition by Dasatinb totally reverted the CXCL10/IP10 induction, further supporting a functional interplay of these factors. Finally, integration of transcriptomics and miRNomics data highlighted several pathways affected by PDGFR-alpha.

This study demonstrates for the first time that PDGFR-alpha strongly inhibits endothelial and melanoma cells proliferation in a CXCL10/IP-10 dependent way, via miR-503 down-regulation.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12629

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

PDGFR-alpha inhibits melanoma growth via CXCL10/IP-10: a multi-omics approach

Abstract